Physician profile
Andrei Carasca
NPI 1992703391
$2,335.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $255 · 2022: $158 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $510.85 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $476.05 | 2019-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $258.39 | 2019-2020 | |
| Genzyme Corporation | $179.54 | 2019-2020 | |
| Allergan, INC. | $166.18 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $111.45 | 2019 | |
| Acorda Therapeutics, INC | $99.04 | 2019 | |
| Sunovion Pharmaceuticals INC. | $89.39 | 2019 | |
| Mdd US Operations, LLC | $89.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $82.22 | 2019 | |
| Vertical Pharmaceuticals, LLC | $66.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $46.57 | 2019 | |
| Banner Life Sciences, LLC | $36.63 | 2022 | |
| Biogen, INC. | $33.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.42 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $26.57 | 2019 | |
| Edw Pharma, INC. | $19.56 | 2019 | |
| Amgen INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Carasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.